Results 81 to 90 of about 9,301 (216)

Systemic antithrombotic effects of ADAMTS13 [PDF]

The Journal of Experimental Medicine, 2006
The metalloprotease ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats 13) cleaves highly adhesive large von Willebrand factor (VWF) multimers after their release from the endothelium. ADAMTS13 deficiency is linked to a life-threatening disorder, thrombotic thrombocytopenic purpura (TTP), characterized by platelet-rich ...
Chauhan, Anil K., Motto, David G., Lamb, Colin B., Bergmeier, Wolfgang, Dockal, Michael, Plaimauer, Barbara, Scheiflinger, Friedrich, Ginsburg, David, Wagner, Denisa D.   +8 more
openaire   +2 more sources

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma

BMC Gastroenterology, 2019
Background To investigate the von Willebrand factor to ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma (HCC) in cirrhosis.
Hiroaki Takaya, Tadashi Namisaki, Mitsuteru Kitade, Kosuke Kaji, Keisuke Nakanishi, Yuki Tsuji, Naotaka Shimozato, Kei Moriya, Kenichiro Seki, Yasuhiko Sawada, Soichiro Saikawa, Shinya Sato, Hideto Kawaratani, Takemi Akahane, Ryuichi Noguchi, Masanori Matsumoto, Hitoshi Yoshiji   +16 more
doaj   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai, Hirohiko Aikawa, Yoshiaki Morita, Keiko Ohta‐Ogo, Teruo Noguchi   +4 more
wiley   +1 more source

Disease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 615-629, June 2026.
ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail, Lynn Warner, Stacey T. Gray, Claire Hopkins, Peter H. Hwang, Sarah K. Wise, Katie M. Phillips, Ahmad R. Sedaghat   +7 more
wiley   +1 more source

The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. [PDF]

, 2014
Acquired thrombotic thrombocytopenic purpura (TTP) is the consequence of a severe ADAMTS13 deficiency resulting from autoantibodies inhibiting ADAMTS13 or accelerating its clearance.
Schaller Tschan, Monica, Kremer Hovinga, Johanna Anna, Vogel, Monique, Kentouche, Karim, Lämmle, Bernhard   +4 more
core   +1 more source

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.

PLoS ONE, 2010
Severe ADAMTS13 deficiency occurs in 13% to 75% of thrombotic microangiopathies (TMA). In this context, the early identification of a severe, antibody-mediated, ADAMTS13 deficiency may allow to start targeted therapies such as B-lymphocytes-depleting ...
Paul Coppo, Michael Schwarzinger, Marc Buffet, Alain Wynckel, Karine Clabault, Claire Presne, Pascale Poullin, Sandrine Malot, Philippe Vanhille, Elie Azoulay, Lionel Galicier, Virginie Lemiale, Jean-Paul Mira, Christophe Ridel, Eric Rondeau, Jacques Pourrat, Stéphane Girault, Dominique Bordessoule, Samir Saheb, Michel Ramakers, Mohamed Hamidou, Jean-Paul Vernant, Bertrand Guidet, Martine Wolf, Agnès Veyradier, French Reference Center for Thrombotic Microangiopathies   +25 more
doaj   +1 more source

Methotrexate Toxicity in a Patient With Renal Failure Despite a Normal Methotrexate Concentration: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Methotrexate (MTX) is a folate antagonist widely used as a disease‐modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA), as well as in several malignancies and autoimmune disorders. Although low‐dose MTX (5–20 mg/week) is generally considered safe, it has a narrow therapeutic index, and toxicity can occur even at therapeutic doses,
Fatemeh Afra, Mahshad Ghoddusi, Mahsa Mottahedi, Maryam Albaji, Samira Kafan, Roya Saedpanah, Amir Shokri, Elham Nazar   +7 more
wiley   +1 more source

IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura [PDF]

, 2009
BACKGROUND: ADAMTS13-neutralizing IgG autoantibodies are the major cause of acquired thrombotic thrombocytopenic purpura (TTP). OBJECTIVE: To analyze the IgG subclass distribution of anti-ADAMTS13 antibodies and a potential relationship between subclass ...
Rieger, M, Ferrari, S, Kremer Hovinga, J A, Veyradier, A, Scheiflinger, F, Mudde, G C   +5 more
core   +1 more source

Integrative genomic and functional characterization of ADAMTS3 reveals its inflammatory regulation via NF‐κB and STAT3 pathways in osteosarcoma

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Abstract Osteosarcoma (OS) is an aggressive bone malignancy characterized by genomic instability and extensive extracellular matrix (ECM) remodeling. Members of the ADAMTS family are matrix‐associated proteases implicated in tumorigenesis; however, their roles in OS remain poorly defined. This study provides a comprehensive genomic, transcriptomic, and
Ehed Muhammed Aymaz, Meltem Alper, Feyza Nur Sav, Tuğşen Aydemir, Feray Köçkar   +4 more
wiley   +1 more source

Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis

International Journal of Hepatology, 2011
The liver plays a central role in hemostasis by synthesizing clotting factors, coagulation inhibitors, and fibrinolytic proteins. Liver cirrhosis (LC), therefore, impacts on both primary and secondary hemostatic mechanisms.
Masahito Uemura, Yoshihiro Fujimura, Saiho Ko, Masanori Matsumoto, Yoshiyuki Nakajima, Hiroshi Fukui   +5 more
doaj   +1 more source